Hypertriglyceridemia: Clinical Trials

28 trials for Hypertriglyceridemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 completed. 28 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 128Completed 28
Phase 27Completed 7

Follow Hypertriglyceridemia: new trials by email Literature Review of Hypertriglyceridemia trials Research Report on Hypertriglyceridemia

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of MAR001 in Adults With Metabolic Dysfunction
MAR001, Placebo - Hypertriglyceridemia
Phase 1 / Phase 2CompletedMarea Therapeutics552023-07-222025-11-13
A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers
VSA003, 0.9% NaCl - Dyslipidemias, Familial Hypercholesterolemia
Phase 1CompletedVisirna Therapeutics HK Limited362023-06-012025-09-12
A Phase 1, First Time in Humans Study of NST-1024
NST-1024, Placebo - Hypertriglyceridemia
Phase 1CompletedNorthSea Therapeutics B.V.962020-10-272022-12-02
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
ARO-APOC3, sterile normal saline (0.9% NaCl) - Hypertriglyceridemia, Familial Chylomicronemia
Phase 1CompletedArrowhead Pharmaceuticals1122019-03-082025-12-24
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
ARO-ANG3, sterile normal saline (0.9% NaCl) - Dyslipidemias, Familial Hypercholesterolemia
Phase 1CompletedArrowhead Pharmaceuticals932019-01-072025-12-24
Study of Gemcabene in Adults With FPLD
300mg Gemcabene, 600mg Gemcabene - Familial Partial Lipodystrophy, Hypertriglyceridemia
Phase 1 / Phase 2CompletedElif Oral52018-03-132020-08-17
Safety Study of LLF580 in Obese Volunteers
LLF580, Placebo - Obesity
Phase 1CompletedNovartis Pharmaceuticals612018-02-262021-10-12
Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia
VAL070-A, VAL070-B, Placebo - Hypercholesterolemia, Hypertriglyceridemia
Phase 1 / Phase 2CompletedValbiotis402017-01-012018-07-05
Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides
APOC-III-L-Rx, Placebo Comparator - Elevated Triglycerides (TG)
Phase 1CompletedIonis Pharmaceuticals, Inc.562016-09-012018-05-22
Vascepa to Accelerate Lipoprotein Uptake and Elimination
Icosapent Ethyl 1000 MG [Vascepa] - Lipid Disorder, Triglycerides High
Phase 1CompletedUniversity of Pennsylvania202016-01-112021-11-11
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia
IONIS ANGPTL3-LRx, Placebo - Hypertriglyceridemia, Familial Hypercholesterolemia
Phase 1CompletedIonis Pharmaceuticals, Inc.482015-11-302020-11-19
A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules
Drug Omega 3, Drug Omega-3 Comparator - Hypertriglyceridemia
Phase 1 / Phase 2CompletedMatinas Biopharma, Inc482014-11-012020-10-12
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Epanova, Lovaza - Severe Hypertriglyceridemia
Phase 1CompletedAstraZeneca302014-10-012016-06-20
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
Metformin Eicosapentaenoate, Metformin HCl and Vascepa - Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
Phase 1CompletedThetis Pharmaceuticals LLC322014-03-012022-05-02
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose - Hypertriglyceridemia
Phase 1CompletedAstraZeneca1142013-09-012016-08-17
Study to Assess the Safety and Tolerability of Single Doses of REGN1500
REGN1500, placebo - Hypertriglyceridemia
Phase 1CompletedRegeneron Pharmaceuticals992012-12-012016-05-12
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects
Simvastatin, acetylsalicylic acid (ASA), omefas - Hypertriglyceridemia
Phase 1CompletedAstraZeneca522011-11-012015-04-30
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
warfarin, omefas, omega-3-acid ethyl esters - Hypertriglyceridemia
Phase 1CompletedAstraZeneca522011-08-012015-04-24
Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
Maraviroc, placebo - Hypertriglyceridemia
Phase 1CompletedWashington University School of Medicine272011-01-012013-12-10
Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects
Diazoxide Choline Controlled-Release Tablet - Hypertriglyceridmia
Phase 1CompletedEssentialis, Inc.92010-10-012014-01-10

Showing 20 of 28. Sign in to see all of them.

Narrower conditions

Dyslipidemias (4)  ·  Hyperlipoproteinemia Type II (3)  ·  Cardiovascular Diseases (2)  ·  Hypercholesterolemia (2)  ·  Hyperlipoproteinemia Type I (2)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Fatty Liver (1)  ·  Hyperlipoproteinemias (1)  ·  Lipid Metabolism Disorders (1)  ·  Lipodystrophy, Familial Partial (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Obesity (1)

Broader conditions

Hyperlipidemias (28)  ·  Metabolic Diseases (28)  ·  Nutritional and Metabolic Diseases (28)  ·  Lipid Metabolism Disorders (27)  ·  Dyslipidemias (24)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Genetic Diseases, Inborn (6)  ·  Lipid Metabolism, Inborn Errors (6)  ·  Metabolism, Inborn Errors (5)  ·  Hyperlipoproteinemias (4)  ·  Endocrine System Diseases (2)  ·  Glucose Metabolism Disorders (2)  ·  Body Weight (1)  ·  Diabetes Mellitus (1)  ·  Digestive System Diseases (1)

Interventions

Omacor (3)  ·  eicosapentaenoic acid ethyl ester (3)  ·  Aspirin (1)  ·  Fatty Acids, Omega-3 (1)  ·  Fenofibrate (1)  ·  Fish Oils (1)  ·  Fructose (1)  ·  Gemfibrozil (1)  ·  Glucose (1)  ·  IONIS-ANGPTL3-LRx (1)  ·  Lopinavir (1)  ·  MAT9001 (1)  ·  Maraviroc (1)  ·  Metformin (1)  ·  Ritonavir (1)

Sponsors

AstraZeneca (4)  ·  Arrowhead Pharmaceuticals (2)  ·  Essentialis, Inc. (2)  ·  Ionis Pharmaceuticals, Inc. (2)  ·  Novartis Pharmaceuticals (2)  ·  Elif Oral (1)  ·  GlaxoSmithKline (1)  ·  Marea Therapeutics (1)  ·  Matinas Biopharma, Inc (1)  ·  National Institutes of Health Clinical Center (CC) (1)  ·  Nordic Pharma, USA (1)  ·  NorthSea Therapeutics B.V. (1)  ·  Regeneron Pharmaceuticals (1)  ·  Rockefeller University (1)  ·  Sanford Research (1)

Countries

United States (17)  ·  Canada (7)  ·  Australia (3)  ·  New Zealand (2)  ·  China (1)  ·  France (1)  ·  United Kingdom (1)

Top investigators

Michael H Davidson, MD, FACC (2)  ·  Alan K Copa, PharmD (1)  ·  Alan K. Copa, Pharm. D. (1)  ·  Alex DePaoli (1)  ·  Andrea L Lawless, MD (1)  ·  Brad West, ND (1)  ·  Elif A Oral, M.D. (1)  ·  Eric Chen, MD (1)  ·  Gregory C Shearer, PhD (1)  ·  Janice Faulknor (1)  ·  John Millar, PhD (1)

Results publications

PMID 21252253, PMID 25393536, PMID 25889044, PMID 28391875, PMID 28538111, PMID 28538136, PMID 31242752, PMID 31329855, PMID 32473640, PMID 33900278, PMID 34431493, PMID 37626170, PMID 38320498, PMID 40383129, PMID 41946917

NIH funding

2015 (1)